All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies

April 25th 2022

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD

April 25th 2022

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL

April 25th 2022

The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.

FDA Grants Priority Review to Tremelimumab/Durvalumab Regimen in Unresectable HCC

April 25th 2022

The FDA has accepted for priority review a biologics license application seeking the approval of a single priming dose of tremelimumab added to regular interval durvalumab in the treatment of patients with unresectable hepatocellular carcinoma.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma

April 25th 2022

Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.

Florida Cancer Specialists & Research Institute Physicians Serve as Panelists for FLASCO Training Program

April 25th 2022

Two medical oncologists from Florida Cancer Specialists & Research Institute participated in the Florida Society of Clinical Oncology Fellow & Resident Educational Training Program. The program featured respected keynote speakers to share helpful information for transitioning into the oncology workforce.

Frontline Axi-cel Elicits Rapid, Durable Responses in High-Risk Large B-Cell Lymphoma

April 24th 2022

The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up

April 24th 2022

The utilization of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphomas produced durable outcomes at a 2 years follow-up.

Belimumab Emerges as Potential Prophylaxis for Chronic GVHD Following Allogenic Transplant

April 24th 2022

Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.

Axi-cel Demonstrates Long-Term Survival Benefit in Relapsed/Refractory LBCL

April 24th 2022

Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24th 2022

Abatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.

EU Panel Recommends Capmatinib for METex14-Altered Advanced NSCLC

April 23rd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization to capmatinib for use as a single agent in select adult patients with advanced non–small cell lung cancer harboring a METex14 skipping alteration.

Adjuvant Atezolizumab Approaches EU Approval for High-Risk NSCLC With PD-L1 of ≥50%

April 22nd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of adjuvant atezolizumab, after complete resection and platinum-based chemotherapy, in adult patients with non–small cell lung cancer with a high risk of recurrence and whose tumors express PD-L1 of 50% or higher and do not harbor EGFR mutations or ALK alterations.

Runyon Foundation Issues $3.6 Million in Grants to Early Career Investigators

April 22nd 2022

The Damon Runyon Cancer Research Foundation awarded a total of $3.6 million to 9 winners of the Damon Runyon-Rachleff Innovation Awards. The grants support investigators whose ideas have the potential to significantly advance the prevention, diagnosis, or treatment of cancer.

Immune Checkpoint Inhibitors, Expanding Trials Signal Progress in Advanced Urothelial Carcinoma

April 22nd 2022

Matthew Galsky, MD, discusses the impact of recent developments in the advanced urothelial carcinoma treatment paradigm.

Total Neoadjuvant Chemotherapy Generates Comparable Efficacy to Chemoradiotherapy in Locally Advanced Rectal Cancer

April 22nd 2022

Short-term radiotherapy followed by total neoadjuvant chemotherapy was found to be noninferior to long-term chemoradiotherapy in patients with locally advanced rectal cancer, according to findings from the phase 3 STELLAR study.

Yale Scientists Discover a New Pathogenic Mechanism in Hematological Malignancies

April 22nd 2022

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.

Targeted Treatment Arsenal for Myelofibrosis Set to Explode

April 22nd 2022

Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis.